Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Healthcare
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar... see more

Recent & Breaking News (NDAQ:SNOA)

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

Accesswire August 11, 2022

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply

Accesswire August 2, 2022

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results

Accesswire July 13, 2022

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

Business Wire June 1, 2022

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.

Business Wire May 3, 2022

Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Business Wire March 30, 2022

Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results

Business Wire February 11, 2022

Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China

Business Wire January 20, 2022

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

Business Wire January 5, 2022

Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results

Business Wire November 15, 2021

Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia

Business Wire November 9, 2021

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Business Wire October 15, 2021

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Business Wire September 28, 2021

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Business Wire August 19, 2021

Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results

Business Wire August 16, 2021

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results

Business Wire July 14, 2021

Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products Nationwide

Business Wire March 31, 2021

SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm

Business Wire March 11, 2021

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - SNOA

Business Wire March 9, 2021

Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences

Business Wire March 4, 2021